Diabetic Macular Edema

Experts in retinal diseases provide insight into when to prescribe VEGF inhibitors and the initial conversations with patients about treatment.

Proportion of eyes with IOP-related events supported monitoring in eyes treated with anti-VEGF therapy for macular edema associated with CRVO or HRVO for up to 60 months.

Phase 3 data show the solution works as fast 15 minutes and lasts for up to 6 hours, to improve near vision without impacting distance vision.

Triamcinolone acetonide injectable suspension has been approved for administration via the suprachoroidal pathway—located in the back of the eye.

A new cross-sectional analysis from ASRS 2021 show White patients are generally overrepresented in randomized, controlled trials for DME.

According to 3x3 mm and 6x6 mm OCTA scans, there were no significant changes in mean macular intercapillary area measures for all tested regions.

Data presented at ADA 2021 supports the noninferiority of faricimab to aflibercept.

Epiretinal membrane and initial detachment of the macula are risk factors for post-operative CME.

Improvements in neovascularization and best-correct visual acuity were generally not sustained following treatment discontinuance.

A systematic review of clinical trials notes that topical eye drops may lead to favorable retinal and visual outcomes, despite heterogeneity across multiple studies.

Dr Arshad Khanani highlights various strategies currently under investigation for the treatment of age-related macular degeneration and explains the impact long-term data and real-world evidence has on his treatment decisions.

Considerations for treating patients with diabetes who have wet age-related macular degeneration with faricimab to reduce treatment burden based on results of recent clinical trials.

Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.

The implant was linked to visual acuity improvements at final follow-up visit.

Animal models suggest the investigative treatment is safe and tolerable in treating retinal vascular diseases.

Up to 77% of patients maintained or improved best-corrected visual acuity at 12 month post-injection.

A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.

CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?

An assessment of VISTA and VIVID patient data uncovered surprising risk factors associated with aflibercept success or failure in DME resolution.

Patients with nAMD, DME, and RVO received fewer intravitreal injections between pre- and post-lockdown periods.

An overview of key clinical trials that have explored the potential of faricimab as a treatment option for patients with wet age-related macular degeneration.

The rationale for studying faricimab, a bispecific antibody that targets 2 distinct pathways, as a treatment option for patients with wet age-related macular degeneration.

An FDA-approved device, provided to eligible patients with age-related macular degeneration, showed ability to detect CNV risks over 5 years.

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.

The PACIFIC study is currently evaluating health care management practice with intravitreal ranibizumab 0.5 mg for various ophthalmologic diseases.

An ARVO 2021 study characterizes patients with diabetic retinopathy who have also developed diabetic macular edema.

Based on personal clinical experience, Arshad Khanani, MD, explains his current approach to treating wet age-related macular degeneration with anti-VEGF therapy, with special considerations for appropriate dosage and timing of injections, and describes how he assesses patient response to therapy.

Dr Arshad Khanani describes the role of anti-VEGF therapy for wet age-related macular degeneration and elaborates on factors that impact treatment selection and sequencing in a patient’s continuum of care.

Strategies that can be used to screen and confirm a diagnosis of age-related macular degeneration, as well as monitor patients to optimize care.